Myelomas
207495: A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM3)
- Details
ClinicalTrials.gov ID:
NCT04162210
Diagnosis Type:
NA
USOR Number:
- Address
2312 N Nevada Ave, Suite 400
Colorado
Springs, CO 80907
P: (719) 577-2555